Skip to main content
OpenTrials
Completed

NCT Number: NCT00478933

DISCOVERY: Diagnostic Data and Genetic Polymorphisms in ICD Patients.

To prospectively evaluate if the analysis of genetic polymorphisms can be used to identify patients at risk of ventricular tachycardia.

To evaluate the influence of ICD-based diagnostic information on the long term treatment and management of primary prevention ICD-patients.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Death, Sudden, Cardiac Arrhythmia, Sinus Arrhythmias, Cardiac Atrial Fibrillation Cardiac Conduction System Disease Cardiovascular Diseases Death Death, Sudden Heart Arrest Heart Block Heart Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms Sick Sinus Syndrome Tachycardia Ventricular Fibrillation

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

About this study

Evaluate the positive predictive value of single nucleotide polymorphisms (SNPs) in the genes GNB3, GNAS and GNAQ as predictors of ventricular arrhythmia <400 msec.

  • Evaluate the positive predictive value of Single Nucleotide Polymorphisms as predictor for death, cardiac death and atrial fibrillation/flutter in the genes GNB3, GNAS, GNAQ and other SNPs involving signal transduction components which impact on the activity of cardiac ion channels.
  • Evaluate the best combination of genetic parameters, baseline data and follow-up data as predictor of primary endpoint, All cause Mortality, cardiac death and atrial arrhythmia.
  • Evaluate the usage of ICD-system diagnostics (battery status, impedance, pacing threshold, sensing) resulting in medical consequences*.
  • Evaluate the usage of ICD-based patient diagnostics (arrhythmia, IEGM, heart frequency, %pacing, Cardiac Compass) resulting in medical consequences*.
  • Evaluate the frequency of programming changes involving AF-prevention and AF-therapy algorithms.
  • Evaluate the frequency of pacing-parameter programming changes and the resulting medical consequences*.
  • Medical consequences include: Hospitalization, medical interventions, medication, surgery, additional diagnostics and ICD-programming changes.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Implantation of a market approved Medtronic Dual-chamber ICD with long term clinical trends Cardiac Compass,
  • Subjects requiring the implantation of an ICD for primary prevention according to the current AHA/ACC/ESC guidelines,
  • Subject able to comply with the Clinical InvestigationPlan,
  • Subject is expected to remain available for follow-up visits,
  • Subject has signed the informed consent form within 10 days of implant,
  • The system implanted for this study is the first ICD implant for patient.

Exclusion criteria

  • Women who are pregnant, or women of childbearing potential not on a reliable form of birth control,
  • Subject is enrolled in a concurrent study that may confound the results of this study,
  • Subject has a life expectancy less than two years,
  • Subject is post heart transplant or awaiting heart transplantation,
  • Subject is anticipated to demonstrate poor compliance,
  • Subjects with syndromes known to be associated with ion channel pathologies such as:
  • Long- or short-QT Syndrome
  • Brugada Syndrome
  • Catecholaminergic Polymorphic Ventricular Tachycardia (CPTV ).

Treatment and study plan

Defibrillator, Dual Chamber ; Implantable

Device

Patient must wear a dual chamber ICD to remain in study. Can be enrolled 10 days prior to implant. Is excluded if device type changes.

blood sampling

Procedure

Blood sampling

Primary outcomes

  1. Number of Patients With Ventricular Arrhythmia <400 Msec. by GNAS c.393C>T Genotype

    Time frame: 2 years

    The GNAS c.393C>T single nucleotide polymorphism (SNP) was one of seven SNP's analyzed. Patients with de novo ICD implants were genotyped and followed for up to 2 years. All episodes of arrhythmia <400 msec. detected by the device were adjudicated by an independent committee. The number of patients with true arrhythmias <400 msec were tracked by genotype.

  2. Number of Patients With Ventricular Arrhythmia <400 Msec. by GNAS c.2273C>T Genotype

    Time frame: 2 years

    The GNAS c.2273C>T single nucleotide polymorphism (SNP) was one of seven SNP's analyzed. Patients with de novo ICD implants were genotyped and followed for up to 2 years. All episodes of arrhythmia <400 msec. detected by the device were adjudicated by an independent committee. The number of patients with true arrhythmias <400 msec were tracked by genotype.

  3. Number of Patients With Ventricular Arrhythmia <400 Msec. by GNAS c.2291C>T Genotype

    Time frame: 2 years

    The GNAS c.2291C>T single nucleotide polymorphism (SNP) was one of seven SNP's analyzed. Patients with de novo ICD implants were genotyped and followed for up to 2 years. All episodes of arrhythmia <400 msec. detected by the device were adjudicated by an independent committee. The number of patients with true arrhythmias <400 msec were tracked by genotype.

  4. Number of Patients With Ventricular Arrhythmia <400 Msec. by GNAQ c.-909/-908GC>TT Genotype

    Time frame: 2 years

    The GNAQ c.-909/-908GC>TT single nucleotide polymorphism (SNP) was one of seven SNP's analyzed. Patients with de novo ICD implants were genotyped and followed for up to 2 years. All episodes of arrhythmia <400 msec. detected by the device were adjudicated by an independent committee. The number of patients with true arrhythmias <400 msec were tracked by genotype.

  5. Number of Patients With Ventricular Arrhythmia <400 Msec. by GNAQ c.-382G>A Genotype

    Time frame: 2 years

    The GNAQ c.-382G>A single nucleotide polymorphism (SNP) was one of seven SNP's analyzed. Patients with de novo ICD implants were genotyped and followed for up to 2 years. All episodes of arrhythmia <400 msec. detected by the device were adjudicated by an independent committee. The number of patients with true arrhythmias <400 msec were tracked by genotype.

  6. Number of Patients With Ventricular Arrhythmia <400 Msec. by GNAQ c.-387G>A Genotype

    Time frame: 2 years

    The GNAQ c.-387G>A single nucleotide polymorphism (SNP) was one of seven SNP's analyzed. Patients with de novo ICD implants were genotyped and followed for up to 2 years. All episodes of arrhythmia <400 msec. detected by the device were adjudicated by an independent committee. The number of patients with true arrhythmias <400 msec were tracked by genotype.

  7. Outcome Measure Title: Number of Patients With Ventricular Arrhythmia <400 Msec. by GNB3 c.825C>T Genotype

    Time frame: 2 years

    The GNB3 c.825C>T single nucleotide polymorphism (SNP) was one of seven SNP's analyzed. Patients with de novo ICD implants were genotyped and followed for up to 2 years. All episodes of arrhythmia <400 msec. detected by the device were adjudicated by an independent committee. The number of patients with true arrhythmias <400 msec were tracked by genotype.

Secondary outcomes

  1. Hospitalization, Medical Interventions, Medication, Surgery, Additional Diagnostics

    Time frame: 2 years

  2. All Cause Mortality, Cardiac Death and Atrial Fibrillation/Flutter

    Time frame: 2 years

Sponsors and collaborators

Lead sponsor

Medtronic Cardiac Rhythm and Heart Failure

Industry

Registry information

Official study title

Diagnostic Data Influence on Disease Management and Relation of Genetic Polymorphisms to Tachy-arrhythmia in ICD Patients.

Acronym: DISCOVERY

Important dates

Study start
2007
Primary completion
2012
Study completion
2012
First posted
May 25, 2007
Registry last updated
Jul 2, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.